Advertisement

Topics

Patient-Experienced Toxicity Is a Biomarker Worth Considering

09:36 EDT 17 Aug 2018 | OncLive

Maurie Markman, MD, says that the acceleration in regulatory agency approvals for novel antineoplastic agents and the focus of biomarker discovery proves that this is the era of precision medicine.

Original Article: Patient-Experienced Toxicity Is a Biomarker Worth Considering

NEXT ARTICLE

More From BioPortfolio on "Patient-Experienced Toxicity Is a Biomarker Worth Considering"

Advertisement
Quick Search
Advertisement
Advertisement